CDKN2A and neoplasm: In the present study, we investigated the promoter methylation levels of MLH1, MGMT, CDKN2A, and RASSF1A in blood and tumor tissue DNA from 69 patients with TAMG, as well as in the healthy thymic epithelial tissue adjacent to the tumor available from 44 of them.